The rapid research being done in the myeloma treatment field means that what we know about current therapies can continue to evolve. With bispecifics being so relatively new as a myeloma treatment, we are certain to see changes as it evolves. 

The following sections will detail information like: 

• What role can bispecific antibody therapy play in eliminating geographic and other medical disparities?
• How is real world data affecting how bispecifics are administered?